Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

Researchers from the Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a promising new drug to treat Alzheimer’s Disease (AD). In a review article, published ...

In July 2023, the United States Food and Drug Administration (FDA) approved lecanemab as a disease-modifying therapy (DMT) to combat early symptomatic AD. Soon thereafter, in July 2024 ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...

In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients with early AD. In December 2024, Eisai requested reconsideration of the decision, ...